



DT06 Rec'd PCT/PTO 30 JUL 2002 PCT

PATENT APPLICATION

Our File No.: 20020113.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Fionula Mary Brennan et al : July 25, 2002  
S.N. : 10/088,801 : Art Unit unknown  
Filed : March 21, 2002  
For : THERAPEUTIC METHODS AND COMPOUNDS

-----  
Hon. Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Applicant(s) herein make available to the Patent and Trademark Office a copy of Form PTO-1449 which lists the following document(s), copies of which are enclosed. This Information Disclosure Statement is being filed in accordance with the following provision(s):

- ☐ 37 CFR 1.97(b)(1) Within three months of the filing date of the national application. No fee is required.
- ☐ 37 CFR 1.97(b)(2) Within three months of the date of entry of the national stage as set forth in § 1.491 in the international application. No fee is required.
- ☒ 37 CFR 1.97(b)(3) Before the mailing date of a first Office Action on the merits. No fee is required.
- ☐ 37 CFR 1.97(c) After the periods specified in 37 CFR 1.97(b), but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

- [ ] The undersigned hereby certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or
- [ ] The undersigned hereby certifies that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; or
- [ ] Enclosed is a check in the amount of \$200.00 for the fee set forth in 37 CFR § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.
- [ ] 37 CFR 1.97(d) After the mailing date of either (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first, but before payment of the issue fee.
- [ ] Applicant(s) hereby petition the Commissioner of Patents and Trademarks to consider this information disclosure statement. Enclosed is a check in the amount of \$130.00 for the petition fee set forth in § 1.17(i)(1). The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 08-1265. Two copies of this sheet are enclosed.

The Examiner is requested to consider carefully the complete text of these documents in connection with the examination of the above-identified application in accordance with 37 CFR 1.104(a). It is requested that the documents listed on the attached Form PTO-

1449 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12), and that the Examiner initial and return a copy of the form to evidence consideration of the documents.

Dated: July 25, 2002.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.



C. G. Mersereau  
Attorney for Applicant(s)  
Registration No. 26,205  
900 Second Avenue South  
Suite 820  
Minneapolis, MN 55402  
Phone: 612-339-7461


#### CERTIFICATE OF MAILING

I hereby certify that the foregoing Information Disclosure Statement Under Rule 1.56, Form PTO-1449 and a copy of each cited reference to be filed in connection with application Serial No. 10/088,801 of inventors, Fionula Mary Brennan, Marc Feldmann and Brian M. J. Foxwell, filed March 21, 2002, for "THERAPEUTIC METHODS AND COMPOUNDS" is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Box DD, Washington, D.C. 20231 on July 25, 2002.



Barbara L. Davis  
Secretary to C. G. Mersereau

Date of Signature: July 25, 2002



(2-92)  
Sheet 3 of 3

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020113.ORI	Application Number 10/088,801
	Applicant Fionula Mary Brennan et al	
	Filing Date March 21, 2002	Group Art Unit

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

"	Crawley et al., JOURNAL OF BIOLOGICAL CHEMISTRY, <i>Interleukin-10 Stimulation of Phosphatidylinositol 3-Kinase and p70 S6 Kinase is Required for the Proliferative but not the Antiinflammatory Effects of the Cytokine</i> , Vol. 271, No. 27, July 5, 1996, pp. 16357-16362 ✓
	Clarke et al, EUR. JOURNAL OF IMMUNOLOGY, <i>Interleukin-4 Inhibits X Light Chain Expression and NFkB Activation but not IxBa Degradation in 70Z/3 Murine Pre-B Cells</i> , Vol. 25, (1995) pp. 2961-2966 ✓
.	McInnes et al, IMMUNOLOGY TODAY, <i>Interleukin 15: A Proinflammatory Role in Rheumatoid Arthritis Synovitis</i> , (1998) Vol. 19, pp. 75-79 ✓
	Shah et al, NATURE MEDICINE, <i>A Role for IL-15 in Rheumatoid Arthritis</i> , (1998) Vol. 4, p 643

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



(2-92)  
Sheet 1 of 3

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020113.ORI	Application Number 10/088,801
	Applicant Fionula Mary Brennan et al	
	Filing Date March 21, 2002	Group Art Unit

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,085,985	02/04/92	Maino et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
			PCT Written Opinion				
	EP 0896 999A1	03/12/97	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Foxwell et al, PROC NAT'L ACAD SCI USA, Efficient Adenoviral Infection with IkBa Reveals that Macrophage Tumor Necrosis Factor a Production in Rheumatoid Arthritis is NF-kB Dependent, Vol. 95, July 1998, pp. 8211-8215 ✓
	Eigler et al, IMMUNOLOGY TODAY, Taming TNF: Strategies to Restrain this Proinflammatory Cytokine, Vol. 18, (1997), pp. 487-492 ✓
	Sebbag et al, EUR J IMMUNOLOGY, Cytokine Stimulation of T Lymphocytes Regulates Their Capacity to Induce Monocyte Production of tumor Necrosis Factor-a, but not Interleukin-10: Possible Revlevance to Pathophysiology of Rheumatoid Arthritis, Vol. 27, (1997), pp. 624-632 ✓
	Ward et al, IMMUNOLOGY TODAY, PI 3-Kinase: a Pivotal Pathway in T-Cell Activation?, Vol. 17, (1996) pp. 187-197 ✓
	Bhattacharyya et al, J LEUCOCYTE BIOLOGY, Activated T Lymphocytes Induce Degranulation and Cytokine Production by Human Mast Cells Following Cell-To-Cell Contact, Vol. 63, (1998), pp. 337-341 ✓
	Chabot et al, J CLIN INVEST, Microglial Production of TNF-a Is Induced by Activated Lymphocytes, Vol. 100, (1997), pp. 604-612 ✓
	Avicé et al, J IMMUNOLOGY, Lymphocyte Activation Gene-3, a MHC Class II Ligand Expressed on Activated T Cells, Stimulates TNF-a and IL-12 Production by Monocytes and Dendritic Cells, Vol. 162, (1999), pp. 2748-2753 ✓

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



(2-92)  
Sheet 2 of 3

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Document Number 20020113.ORI	Application Number 10/088,801
	Applicant Fionula Mary Brennan et al	
	Filing Date March 21, 2002	Group Art Unit

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	MacLean et al., JOURNAL OF IMMUNOLOGY, Anti-CD3:Anti-IL-2 Receptor Bispecific Monoclonal Antibody, Vol. 150, No. 4, February 15, 1993, pp. 1619-1628 ✓
	Londei et al, Symposium on Molecular and Cellular Mechanisms of Human Hypersensitivity and Autoimmunity Held at the 17 <sup>th</sup> Annual UCLA Symposia on Molecular and Cellular Biology, Cloning of Activated T Cells From Rheumatoid Arthritis Joints: Detection of Collagen type II Specific Cells, (1988) Abstract
	Cohen et al, ARTHRITIS AND RHEUMATISM, High Level of Interleukin-10 Production by the Activated T Cell Population Within the Rheumatoid Synovial Membrane, Vol. 38, No. 7, July 1995, pp. 946-952 ✓
	Bondeson et al, Proc. Natl. Acad. Sci USA, Defining Therapeutic Targets by Using Adenovirus: Blocking NF-kB Inhibits Both Inflammatory and Destructive Mechanisms in Rheumatoid Synovium but Spares Anti-Inflammatory Mediators, Vol. 96, (1999) pp. 5668-5673 ✓
	Carson, NATURE MEDICINE, Unconventional T-Cell Activation by IL-15 in Rheumatoid Arthritis, Vol. 3, (1997), pp. 148-149 ✓
	McInnes et al, NATURE MEDICINE, Interleukin-15 Mediates T Cell-Dependent Regulation of Tumor Necrosis Factor- $\alpha$ Production in Rheumatoid Arthritis, Vol. 3, (1997), pp. 189-195 ✓
	Yocum, SEMINARS IN ARTHRITIS AND RHEUMATISM, T Cells: Pathogenic Cells and Therapeutic Targets in Rheumatoid Arthritis, Vol. 29, (1999), pp. 27-35 ✓

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.